INTRODUCTION: Transanal one-stage endorectal pull-through (TOSEPT) has been presented as the most recent progression in the treatment of Hirschsprung's disease (HD), which may be able to replace various previous techniques. This prospective study was designed to evaluate the efficacy and probable complications of this procedure in management of newborns with HD. MATERIALS AND METHODS: Fifty-one newborns (33 boys and 18 girls) underwent TOSEPT; all after being diagnosed by barium enema and rectal biopsy over a 52-month period. All patients were followed-up up from 6 to 48 months after hospital discharge. RESULTS: There was no per-operative complication. Laparotomy was necessary in five children (9.8%). Average length of aganglionosis segment was 13.9 cm +/- 6.0 cm. Mean postoperative hospitalization time was 7.1 days. TOSEPT was redone in two patients (3.9%) because of aganglionosis segment remaining. After 6-48 months of follow-up, all children have been well now. CONCLUSION: Our data suggested that TOSEPT is efficacious and safe in the management of newborn with HD.
INTRODUCTION: Transanal one-stage endorectal pull-through (TOSEPT) has been presented as the most recent progression in the treatment of Hirschsprung's disease (HD), which may be able to replace various previous techniques. This prospective study was designed to evaluate the efficacy and probable complications of this procedure in management of newborns with HD. MATERIALS AND METHODS: Fifty-one newborns (33 boys and 18 girls) underwent TOSEPT; all after being diagnosed by barium enema and rectal biopsy over a 52-month period. All patients were followed-up up from 6 to 48 months after hospital discharge. RESULTS: There was no per-operative complication. Laparotomy was necessary in five children (9.8%). Average length of aganglionosis segment was 13.9 cm +/- 6.0 cm. Mean postoperative hospitalization time was 7.1 days. TOSEPT was redone in two patients (3.9%) because of aganglionosis segment remaining. After 6-48 months of follow-up, all children have been well now. CONCLUSION: Our data suggested that TOSEPT is efficacious and safe in the management of newborn with HD.
Authors: G Podevin; H Lardy; O Azzis; S Branchereau; T Petit; R Sfeir; D Weil; Y Heloury; B Fremond Journal: Eur J Pediatr Surg Date: 2006-04 Impact factor: 2.191
Authors: D H Teitelbaum; R E Cilley; N J Sherman; D Bliss; N D Uitvlugt; E J Renaud; I Kirstioglu; T Bengston; A G Coran Journal: Ann Surg Date: 2000-09 Impact factor: 12.969
Authors: Anu Paul; Nia Fraser; Sumita Chhabra; Iain E Yardley; Brian W Davies; Shailinder J Singh Journal: Pediatr Surg Int Date: 2007-12 Impact factor: 1.827
Authors: Jacob C Langer; Audrey C Durrant; Luis de la Torre; Daniel H Teitelbaum; Robert K Minkes; Michael G Caty; Barbara E Wildhaber; S Jose Ortega; Shinjiro Hirose; Craig T Albanese Journal: Ann Surg Date: 2003-10 Impact factor: 12.969
Authors: Laurens D Eeftinck Schattenkerk; Gijsbert D Musters; David J Nijssen; Wouter J de Jonge; Ralph de Vries; L W Ernest van Heurn; Joep P M Derikx Journal: Innov Surg Sci Date: 2021-08-17
Authors: Wesam Mohamed; Mohamed I Elsawaf; Aly I Shalaby; Ahmed E Arafat; Mahmoud M Marei; Mohamed H Aboulfadl; Sherif N Kaddah; Gamal H El Tagy; Khaled H K Bahaaeldin Journal: J Indian Assoc Pediatr Surg Date: 2021-01-11